Trial Profile
The Protective Effect of the α2-agonist Dexmedetomidine on Mitochondrial Structure and Function for Children With Non-cyanotic Congenital Heart Defects Having Cardiac Surgery: A Randomized Controlled Trial.
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 04 May 2020
Price :
$35
*
At a glance
- Drugs Dexmedetomidine (Primary)
- Indications Postoperative ischaemia; Reperfusion injury
- Focus Pharmacodynamics
- 08 May 2018 Planned End Date changed from 1 Dec 2017 to 1 Dec 2019.
- 08 May 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2019.
- 03 Nov 2016 Planned End Date changed from 1 May 2017 to 1 Dec 2017.